Cancer NetworkOriginal article
<![CDATA[Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer]]>
Phase 2positivedostarlimabPositive
AI Analysis
Summary
Interim Phase 2 AZUR-1 trial data demonstrates sustained clinical complete responses with dostarlimab monotherapy in patients with dMMR/MSI-H locally advanced rectal cancer.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
Sustained clinical complete responses with dostarlimab monotherapy in dMMR/MSI-H locally advanced rectal cancer
Importance:7/10
Sentiment:
0.75
oncologyrectal cancerimmunotherapydMMRMSI-Hclinical trialcomplete response
Related Companies
Read the original article
Published by Cancer Network on July 13, 2026 3:30 PM